ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression

Blood

Volumn 107, Issue 8, 2006, Pages 3330-3338

  Mueller, Beatrice U ^a   Pabst, Thomas ^b   Fos, José ^b   Petkovic, Vibor ^b   Fey, Martin F ^b   Asou, Norio ^b   Buergi, Ulrich ^b   Tenen, Daniel G ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; HYBRID PROTEIN; OCTAMER TRANSCRIPTION FACTOR 1; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; NEUTROPHIL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

EID: 33645734361     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-3068     Document Type: Article

References (33)

1. Klemsz MJ, McKercher SR, Celada A, Van Beveren C, Maki RA. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell. 1990;61:113-124.
2. Hromas R, Orazi A, Neiman RS, et al. Hematopoietic lineage-restricted and stage-restricted expression of the ETS oncogene family member PU.1. Blood. 1993;82:2998-3004.
3. Chen HM, Zhang P, Voso MT, et al. Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. Blood. 1995;85:2918-2928.
4. Nutt SL, Metcalf D, D'Amico A, Polli M, Wu L. Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J Exp Med. 2005;201:221-231.
5. Back J, Allman D, Chan S, Kastner P. Visualizing PU.1 activity during hematopoiesis. Exp Hematol. 2005;33:395-402.
6. Voso MT, Burn TC, Wulf G, et al. Inhibition of hematopoiesis by competitive binding of the transcription factor PU.1. Proc Natl Acad Sci U S A. 1994;91:7932-7936.
7. Nerlov C, Graf T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev. 1998;12:2403-2412.
8. Scott EW, Simon MC, Anastai J, Singh H. The transcription factor PU.1 is required for the development of multiple hematopoietic lineages. Science. 1994;265:1573-1577.
9. McKercher SR, Torbett BE, Anderson KL, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 1996;15:5647-5658.
10. Anderson KL, Smith KA, Pio F, Torbett BE, Maki RA. Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent. Blood. 1998;92:1576-1585.
11. Mueller BU, Pabst T, Osato M, et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood. 2002;100:998-1007.
12. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004;36:624-630.
13. Cook WD, McCaw BJ, Herring C, et al. PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood. 2004;104:3437-3444.
14. Suraweera N, Meijne E, Moody J, et al. Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia. Oncogene. 2005;19:3678-3683.
15. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
16. Nervi C, Ferrara FF, Fanelli M, et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood. 1998;92:2244-2251.
17. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998;391:815-818.
18. Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811-814.
19. Tenen DG, Hromas R, Licht JD, Zhang D-E. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489-519.
20. Duprez EA, Koch H, Wagner K, Tenen DG. C/EBPβ: a major PML/RARA responsive gene mediating granulopoiesis in retinoic acid-induced APL cell differentiation. EMBO J. 2003;22:5806-5816.
21. Smith LT, Hohaus S, Gonzalez DA, Dziennis SE, Tenen DG. PU.1 (Spi-1) and C/EBPα regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood. 1996;88:1234-1247.
22. Zhang D-E, Hetherington CJ, Chen HM, Tenen DG. The macrophage transcription factor PU.1 directs tissue specific expression of the macrophage colony stimulating factor receptor. Mol Cell Biol. 1994;14:373-381.
23. Devroe E, Silver PA. Retrovirus-delivered siRNA. BMC Biotechnol. 2002;2:15.
24. Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RAR-alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74:423-431.
25. Kishi K, Toba K, Azegami T, et al. Hematopoietic cytokine-dependent differentiation to eosinophils and neutrophils in a newly established acute promyelocytic leukemia cell line with t(15;17). Exp Hematol. 1998;26:135-142.
26. Lanotte M, Martin-Thouvenin V, Najman S, et al. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 1991;77:1080-1086.
27. Chen HM, Ray-Gallet D, Zhang P, et al. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene. 1995;11:1549-1560.
28. Chen HM, Zhang P, Radomska HS, et al. Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. J Biol Chem. 1996;271:15743-15752.
29. Truong BTH, Lee YJ, Lodie TA, et al. CCAAT/enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood. 2003;101:1141-1148.
30. Moreau-Gachelin F, Wendling F, Molina T, et al. Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol. 1996;16:2453-2463.
31. Lamandin C, Sagot C, Roumier C, et al. Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood. 2002;100:4680-4681.
32. Kistler B, Pfisterer P, Wirth T. Lymphoid- and myeloid-specific activity of the PU.1 promoter is determined by the combinatorial action of octamer and ets transcription factors. Oncogene. 1995;11: 1095-1106.
33. Park DJ, Chumakov AM, Vuong PT, et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J Clin Invest. 1999;103:1399-1408.